Skip to main content
. 2017 Dec 14;39(7):1189–1196. doi: 10.1038/aps.2017.167

Figure 2.

Figure 2

Per-protocol-analysis of novel cardiovascular biomarkers in CHF patients. sST2 levels did not significantly change (A). GDF-15 and H-FABP levels decreased significantly after 6 months of treatment with Ivabradine (B, C). suPAR concentrations increased over the follow-up period (D).